- Published at
- by investing.com
neutral
neutral
Qurient Launches Clinical Trial for Acute Myeloid Leukemia Treatment with Adrixetinib (Q702) By Investing.com
Qurient Launches Clinical Trial for Acute Myeloid Leukemia Treatment with Adrixetinib (Q702)
News for Qurient Co., Ltd. (115180.KQ)
- Published at
- by globenewswire.com
mixedmixedHepatic Tumor Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the Domain
Hepatic tumors are abnormal growth of liver cells on or in the liver. The Hepatic Tumor market is driven by several key factors reflecting the increasing...- Published at
- by globenewswire.com
mixedmixedCervical Dysplasia Market Size and Share to Rise by 2032, Assesses DelveInsight | Key Companies - GlaxoSmithKline, Merck, Frantz Viral, Brooklyn ImmunoTherapeutics, PapiVax, Inovio
The cervical dysplasia market is expected to grow significantly owing to an increased screening rate and increasing initiatives to create public awareness....- Published at
- by prnewswire.com
negativenegativeLiver Cancer Market to Proliferate Positively, Assesses DelveInsight | Key Companies Active in the Domain - SOTIO, GlaxoSmithKline, Pfizer, Merck, Takeda, Genentech, Boehringer Ingelheim, DNAtrix, Cel
/PRNewswire/ -- DelveInsight's Liver Cancer Market Insights report includes a comprehensive understanding of current treatment practices, liver cancer emerging...- Published at
- by globenewswire.com
mixedmixedCervical Cancer Market Size is Likely to Increase, Examines DelveInsight | Key Companies in the Market - Gilead, Roche, Genentech, Iovance, Bristol-Myers Squibb, Exelixis, Xencor, Merck, EMD Serono, P
The cervical cancer market is expected to grow due to factors like an increase in the patient pool, rising awareness of the disease, an increase in...- Published at
- by globenewswire.com
mixedmixedCyclin-Dependent Kinase Inhibitor Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 50+ Leading Players Wheeling the Therapeutics Landscape
The prevalence of Cancer has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of...- Published at
- by prnewswire.com
positivepositiveQurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent
/PRNewswire/ -- Qurient Co. Ltd. ("Qurient", KRX: 115180), a clinical-stage biotechnology company based in South Korea, and TB Alliance, a not-for-profit...- Published at
- by prnewswire.com
mixedmixedGastric Cancer Pipeline Space Brims With Novel Emerging Therapies with Over 200 Key Companies Working in the Domain | DelveInsight
/PRNewswire/ -- DelveInsight's 'Gastric Cancer Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline...- Published at
- by globenewswire.com
mixedmixedLiver Cancer Pipeline Insight | Clinical Trial Research Evaluation Report
DelveInsight’s liver cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for liver cancer...